Medicines
Medicines that contribute to improving health worldwide.
Our medicines aim to improve patients’ lives
AstraZeneca is responding to a changing world and an increasing burden of disease by advancing one of the strongest and most productive pipelines in our industry and working to deliver life-changing medicines to patients around the world.
In Switzerland, AstraZeneca has a broad portfolio of prescription drugs in the following therapeutic areas
Cardiovascular disease
ATACAND
ATACAND PLUS
BRILIQUE
CRESTASTATIN
CRESTOR
INDERAL
PEMZEK
PEMZEK PLUS
PLENDIL 5 MG/10 MG/SENIOR 2,5 MG
TENORETIC/- MITE
TENORMIN/- MITE/- SUBMITE
ZESTORETIC/- MITE
ZESTRIL
You can find specialist and patient information at www.swissmedicinfo.ch
Diabetes
BYDUREON
BYETTA
FORXIGA
KOMBIGLYZE XR
ONGLYZA
QTERN
XIGDUO XR
You can find specialist and patient information at www.swissmedicinfo.ch
Oncology
ARIMIDEX
CASODEX
FASLODEX
IMFINZI
IRESSA
LYNPARZA 50 MG KAPSELN
LYNPARZA FILMTABLETTEN
NOLVADEX
TAGRISSO
ZOLADEX
ZOLADEX LA
You can find specialist and patient information at www.swissmedicinfo.ch
Respiratory
DOSIERAEROSOL
BRICANYL TURBUHALER
DAXAS
EKLIRA GENUAIR
FASENRA
OXIS 6/12 TURBUHALER
PULMICORT
RHINOCORT, TURBUHALER
SYMBICORT
VANNAIR 100/6, 200/6
You can find specialist and patient information at www.swissmedicinfo.ch
Central nervous system
SEQUASE XR
SEQUASE
SEROQUEL XR
SEROQUEL
You can find specialist and patient information at www.swissmedicinfo.ch
Patient Safety
Patient safety is a top priority for AstraZeneca. That's why we review, document and analyse all information about adverse events and adverse reactions worldwide. Our aim is to monitor known risks and to identify unknown risks as quickly as possible and provide immediate information.
Help us by reporting side effects and adverse events!
Reporting side effects or adverse events
Tel.: +41 41 725 77 77
We need at least the following information:
- Which AstraZeneca drug was used?
- What event was observed?
- Who is affected? (Initials, sex, age of the patient)
- Contact details of the reporting person for further inquiries
CH-2335; 03/2020